Laura A Petrillo1,2, Areej El-Jawahri2,3, Ryan D Nipp2,3, Morgan R L Lichtenstein4, Sienna M Durbin2, Kerry L Reynolds2,3, Joseph A Greer2,5, Jennifer S Temel2,3, Justin F Gainor2,3. 1. Department of Medicine, Division of Palliative Care and Geriatrics, Massachusetts General Hospital, Boston, Massachusetts. 2. Harvard Medical School, Boston, Massachusetts. 3. Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital, Boston, Massachusetts. 4. Department of Medicine, Division of Hematology and Oncology, Columbia University Medical Center, New York, New York. 5. Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts.
Abstract
BACKGROUND: Adults with impaired performance status (PS) often receive immune checkpoint inhibitors (ICIs) for advanced non-small cell lung cancer (NSCLC) despite limited efficacy data and unknown effects on end-of-life care. METHODS: This was a retrospective, single-site study of 237 patients with advanced NSCLC who initiated ICI treatment from 2015 to 2017. Cox regression was used to compare the overall survival (OS) of patients who had impaired PS (≥2) at the start of ICI treatment with those who had PS 0 or 1 using Cox regression. Logistic regression was conducted to analyze the association between ICI use in the last 30 days of life and the use of end-of-life health care. RESULTS: The patient mean age at ICI initiation was 67 years (range, 37-91 years), and 35.4% of patients had PS ≥2. Most patients (80.8%) received ICI as second-line or later therapy. The median OS was 4.5 months in patients with PS ≥2 and 14.3 months in those with PS 0 or 1 (hazard ratio, 2.5; P < .0001). Among the patients who died (n = 184), 28.8% who had PS ≥2 received ICIs in their last 30 days of life compared with 10.8% of those who had PS 0 or 1 (P = .002). Receipt of ICI in the last 30 days of life was associated with decreased hospice referral (odds ratio, 0.29; P = .008) and increased in-hospital deaths (odds ratio, 6.8; P = .001), independent of PS. CONCLUSIONS: Adults with advanced NSCLC and impaired PS experience significantly shorter survival after ICI treatment and receive ICIs near death more often than those with better PS. Receipt of an ICI near death was associated with lower hospice use and an increased risk of death in the hospital. These results underscore the need for high-quality communication about potential tradeoffs of ICIs, particularly among adults receiving ICIs as second-line or later therapy.
BACKGROUND: Adults with impaired performance status (PS) often receive immune checkpoint inhibitors (ICIs) for advanced non-small cell lung cancer (NSCLC) despite limited efficacy data and unknown effects on end-of-life care. METHODS: This was a retrospective, single-site study of 237 patients with advanced NSCLC who initiated ICI treatment from 2015 to 2017. Cox regression was used to compare the overall survival (OS) of patients who had impaired PS (≥2) at the start of ICI treatment with those who had PS 0 or 1 using Cox regression. Logistic regression was conducted to analyze the association between ICI use in the last 30 days of life and the use of end-of-life health care. RESULTS: The patient mean age at ICI initiation was 67 years (range, 37-91 years), and 35.4% of patients had PS ≥2. Most patients (80.8%) received ICI as second-line or later therapy. The median OS was 4.5 months in patients with PS ≥2 and 14.3 months in those with PS 0 or 1 (hazard ratio, 2.5; P < .0001). Among the patients who died (n = 184), 28.8% who had PS ≥2 received ICIs in their last 30 days of life compared with 10.8% of those who had PS 0 or 1 (P = .002). Receipt of ICI in the last 30 days of life was associated with decreased hospice referral (odds ratio, 0.29; P = .008) and increased in-hospital deaths (odds ratio, 6.8; P = .001), independent of PS. CONCLUSIONS: Adults with advanced NSCLC and impaired PS experience significantly shorter survival after ICI treatment and receive ICIs near death more often than those with better PS. Receipt of an ICI near death was associated with lower hospice use and an increased risk of death in the hospital. These results underscore the need for high-quality communication about potential tradeoffs of ICIs, particularly among adults receiving ICIs as second-line or later therapy.
Authors: Kennedy Yao Yi Ng; Sze Huey Tan; Jack Jie En Tan; Desiree Shu Hui Tay; Ailica Wan Xin Lee; Andrea Jing Shi Ang; Lawrence Wen Jun Wong; Su Pin Choo; David Wai-Meng Tai; Joycelyn Jie Xin Lee Journal: Liver Cancer Date: 2021-10-26 Impact factor: 11.740
Authors: Laura A Petrillo; Kerry L Reynolds; Sienna M Durbin; Leyre Zubiri; Andrzej Niemierko; Aditya Bardia; Ryan J Sullivan; Corey McEwen; Therese M Mulvey; Ian M Allen; Donald P Lawrence; Justine V Cohen; Ephraim P Hochberg; David P Ryan Journal: Oncologist Date: 2020-11-08
Authors: Ali Raza Khaki; Shasank Chennupati; Catherine Fedorenko; Li Li; Qin Sun; Petros Grivas; Scott D Ramsey; Stephen M Schwartz; Veena Shankaran Journal: JCO Oncol Pract Date: 2021-05-19
Authors: Kartik Sehgal; Ritu R Gill; Page Widick; Poorva Bindal; Danielle C McDonald; Meghan Shea; Deepa Rangachari; Daniel B Costa Journal: JAMA Netw Open Date: 2021-02-01